Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074542 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Tillotts Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 364
- Enrollment target
- 20
- Study locations
NCT00074542 is a Phase 3 study of Crohn's Disease that has completed, run by Tillotts Pharma. The registered enrollment target is 364 participants, below the 2,391-participant average among 105 other Crohn's Disease trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00074542, a Phase 3 study of Crohn's Disease, has completed, sponsored by Tillotts Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 364 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy. Patient safety and quality of life will also be monitored throughout the study.
Conditions Studied
Interventions
- DRUG Epanova™ (Omega-3 Free Fatty Acids)
Study Locations (20)
Illinois
- Northwestern University Medical School - Chicago
- University of Chicago Medical Center - Chicago
- Carle Clinic Association - Urbana
Alberta
- Health Sciences Centre - Calgary
- Royal Alexandra Hospital - Edmonton
- University of Alberta - Edmonton
Ontario
- London Health Sciences Centre (South Street Campus) - London
- London Health Sciences Centre (University Campus) - London
- The Ottawa Hospital (Civic Campus) - Ottawa
British Columbia
- Vancouver General Hospital - Vancouver
- St. Paul's Hospital - Vancouver
Georgia
- Atlanta Gastroenterology Associates - Atlanta
Kentucky
- University of Louisville, Department of Surgery - Louisville
Minnesota
- Mayo Clinic - Rochester
Nebraska
- Gastroenterology Specialties, P.C. - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2002-09 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074542
The ClinicalTrials.gov registry entry for NCT00074542 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,391-participant average among 105 other Crohn's Disease trials with a reported enrollment target (85% lower). The listed sponsor is Tillotts Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Epanova™ (Omega-3 Free Fatty Acids) is the first listed.
NCT00074542 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Illinois, Alberta, Ontario.
Frequently Asked Questions
What is clinical trial NCT00074542 about?
NCT00074542 is a clinical study titled "An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease". The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy. Patient safety and quality of life will also be monitored throughout the study.
What is the current status of trial NCT00074542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 364 participants. The study started on 2002-09. Estimated completion is 2005-01.
What conditions does trial NCT00074542 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00074542?
The interventions under investigation include: Epanova™ (Omega-3 Free Fatty Acids) (DRUG).
Who is sponsoring clinical trial NCT00074542?
This trial is sponsored by Tillotts Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00074542 being conducted?
This trial has 20 study locations across Georgia, Illinois, Kentucky, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.